How Has the Hereditary Angioedema Therapeutics Market Size Evolved in Recent Years?
The hereditary angioedema therapeutics market has seen considerable growth due to a variety of factors.
•The market size for therapeutics in hereditary angioedema has seen a significant surge in the past few years. A rise from $6.68 billion in 2024 to $7.84 billion in 2025, marking a Compound Annual Growth Rate (CAGR) of 17.3%.
is projected for this market. The reasons for the growth during the historical period are due to enhanced diagnostic procedures and awareness, extended access to treatment, research and development projects, patient support and learning opportunities, as well as regulatory endorsements.
What are the Market Size and Expected Growth Rates for the Hereditary Angioedema Therapeutics Market?
The hereditary angioedema therapeutics market is expected to maintain its strong growth trajectory in upcoming years.
• The market size for therapeutics focused on hereditary angioedema is forecasted to experience brisk growth in the coming years. It is projected to expand to a value of $16.11 billion by 2029, with a compound annual growth rate (CAGR) of 19.7%.
This substantial growth during the forecast period is primarily due to advances in specific therapies, worldwide market growth, progress in gene therapy, trends in personalized medicine, and partnerships in research and treatment. The key trends to watch in the forecast period are initiatives for global accessibility, research on health economic outcomes, strategies for early intervention, and hereditary angioedema treatments for children.
Which Drivers Are Accelerating Growth In The Hereditary Angioedema Therapeutics Market?
The hereditary angioedema market is forecasted to expand due to the increasing occurrence of the genetic disorder. Hereditary angioedema, a rather uncommon genetic anomaly, is known for recurrent severe swelling episodes affecting the skin and mucus membranes as a result of excessive fluid accumulation, or Edema. This swelling can be experienced anywhere in the body such as hands, feet, face, intestines, and respiratory tract. As stated by Rare Disease Advisor, an international online health provider, in June 2022, the global occurrence of hereditary angioedema is 1 in every 50,000 people, with prevalence estimates spanning from 1:10,000 to 1:150,000. Each year in the U.S, hereditary angioedema episodes result in between 15,000 to 30,000 emergency room visits. A section of 5.8% of HAE cases show an average diagnosis time of 0 to 6 months, while another 5.8% depict an average diagnosis time exceeding 10 years. Consequently, the escalating incidence of hereditary angioedema is stimulating the growth of the related market.
What Are The Core Segments Of The Global Hereditary Angioedema Therapeutics Market?
The hereditary angioedema therapeutics market covered in this report is segmented –
1) By Drug Class: C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor, Other Drug Classes
2) By Route of Administration: Intravenous, Subcutaneous, Oral
3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels
4) By Application: Prophylaxis, On-demand
Subsegments:
1) By C1 Esterase Inhibitor: Plasma-Derived, Recombinant
2) By Selective Bradykinin B2 Receptor Antagonist: Icatibant
3) By Kallikrein Inhibitor: Ecallantide, Lanadelumab
4) By Other Drug Classes: Emerging Therapies
Pre-Book The Hereditary Angioedema Therapeutics Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
Which Emerging Trends Are Reshaping The Hereditary Angioedema Therapeutics Market Size?
The hereditary angioedema therapeutics market is seeing a rise in the trend of product innovations. Several leading firms in this market are creating groundbreaking products like ligand-conjugated (LICA) experimental antisense drugs and gene therapy in order to consolidate their market stand. For example, in March 2023, Intellia Therapeutics, an American clinical-stage biotech firm, introduced an Investigational New Drug (IND), NTLA-2002, which received approval from the US Food and Drug Administration for the treatment of hereditary angioedema. This approval broadens the scope of the company’s ongoing Phase 1/2 trial to include the US in the global Phase 2 segment. The action of the target gene, kallikrein B1 (KLKB1), is permanently reduced, and HAE attacks are prevented after a single treatment dose. NTLA-2002 is being considered as a potential in vivo genome editing candidate.
Who Are the Key Players in the Hereditary Angioedema Therapeutics Market?
Major companies operating in the hereditary angioedema therapeutics market include:
• Sanofi S.A.
• Pharming Healthcare Inc.
• Attune Pharmaceuticals Inc.
• Adverum Biotechnologies Inc.
• Arrowhead Pharmaceuticals Inc.
• Ionis Pharmaceuticals Inc.
• BioCryst Pharmaceuticals Inc.
• CSL Behring LLC
• KalVista Pharmaceutical Inc.
• CENTOGENE N.V.
• GlaxoSmithKline plc.
• Eli Lilly and Company
• Amgen Inc.
• AbbVie Inc.
• Incyte Corporation
• BioMarin Pharmaceutical Inc.
• Dyax Corp.
• Salix Pharmaceuticals Inc.
• Pharvaris N.V.
• Innovent Biologics Inc.
• AstraZeneca plc
• BeiGene Ltd.
• Jiangsu HenGrui Medicine Co. Ltd.
• Bristol-Myers Squibb Company
• F. Hoffmann-La Roche AG .
• Exelixis Inc.
• Lev Pharmaceuticals Inc.
• Kedrion Biopharma Inc.
• Pharos Pharmaceuticals Inc.
What are the Regional Insights into the Hereditary Angioedema Therapeutics Market?
North America was the largest region in the global hereditary angioedema therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hereditary angioedema therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
